BACKGROUND: The risks for cancers other than breast (BC) or ovarian (OC) cancer in breast cancer gene 1 and 2 (BRCA1/2) mutation carriers were elevated in studies of carrier families. However, case-control studies did not confirm this observation. OBJECTIVE: To compare the risks for other cancers in BRCA1/2 mutation carriers and non-carriers, all affected with BC and/or OC. Both groups share risk modifiers of BC/OC, which enabled assessment of the role of BRCA1/2 mutations. METHODS: 1098 Ashkenazi Jewish women affected with BC and/or OC were ascertained during 1995-2003; molecular testing revealed 229 BRCA1 and 100 BRCA2 carriers and 769 non-carriers. COX proportional hazard models were used to evaluate the risk of other cancers. Analyses were conducted including all other cancers or only those diagnosed after BC/OC diagnosis. RESULTS: The HRs for any other cancer were 2.6 (95% CI 1.7 to 4.2, p<0.001) and 1.8 (95% CI 0.95 to 3.6, p = 0.07) in BRCA1 and BRCA2 carriers, respectively. The corresponding colon cancer HRs were 3.9 (95% CI 1.3 to 12.1, p = 0.02) and 2.3 (95% CI 0.5 to 11.3, p = 0.3) in BRCA1 and BRCA2 carriers. The HR for lymphoma was 11.9 (95% CI 3.1 to 46.2, p = 0.001) in BRCA2 carriers. Risk estimates for other cancers after the onset of BC/OC were similar. CONCLUSION: A 2.5-fold increase in any other cancer and a fourfold risk of colon cancer were found among BRCA1 carriers. The corresponding HRs in BRCA2 carriers were non-significant, except for the markedly elevated risk of lymphoma. These results suggest a role for BRCA1/2 mutations in colorectal cancer risk in a subgroup of BC/OC-affected carriers.
BACKGROUND: The risks for cancers other than breast (BC) or ovarian (OC) cancer in breast cancer gene 1 and 2 (BRCA1/2) mutation carriers were elevated in studies of carrier families. However, case-control studies did not confirm this observation. OBJECTIVE: To compare the risks for other cancers in BRCA1/2 mutation carriers and non-carriers, all affected with BC and/or OC. Both groups share risk modifiers of BC/OC, which enabled assessment of the role of BRCA1/2 mutations. METHODS: 1098 Ashkenazi Jewish women affected with BC and/or OC were ascertained during 1995-2003; molecular testing revealed 229 BRCA1 and 100 BRCA2 carriers and 769 non-carriers. COX proportional hazard models were used to evaluate the risk of other cancers. Analyses were conducted including all other cancers or only those diagnosed after BC/OC diagnosis. RESULTS: The HRs for any other cancer were 2.6 (95% CI 1.7 to 4.2, p<0.001) and 1.8 (95% CI 0.95 to 3.6, p = 0.07) in BRCA1 and BRCA2 carriers, respectively. The corresponding colon cancer HRs were 3.9 (95% CI 1.3 to 12.1, p = 0.02) and 2.3 (95% CI 0.5 to 11.3, p = 0.3) in BRCA1 and BRCA2 carriers. The HR for lymphoma was 11.9 (95% CI 3.1 to 46.2, p = 0.001) in BRCA2 carriers. Risk estimates for other cancers after the onset of BC/OC were similar. CONCLUSION: A 2.5-fold increase in any other cancer and a fourfold risk of colon cancer were found among BRCA1 carriers. The corresponding HRs in BRCA2 carriers were non-significant, except for the markedly elevated risk of lymphoma. These results suggest a role for BRCA1/2 mutations in colorectal cancer risk in a subgroup of BC/OC-affected carriers.
Authors: Catherine M Phelan; Elaine Kwan; Elaine Jack; Song Li; Cindy Morgan; Jennifer Aubé; Danielle Hanna; Steven A Narod Journal: Hum Mutat Date: 2002-11 Impact factor: 4.878
Authors: C J van Asperen; R M Brohet; E J Meijers-Heijboer; N Hoogerbrugge; S Verhoef; H F A Vasen; M G E M Ausems; F H Menko; E B Gomez Garcia; J G M Klijn; F B L Hogervorst; J C van Houwelingen; L J van't Veer; M A Rookus; F E van Leeuwen Journal: J Med Genet Date: 2005-09 Impact factor: 6.318
Authors: G R Howe; T Hirohata; T G Hislop; J M Iscovich; J M Yuan; K Katsouyanni; F Lubin; E Marubini; B Modan; T Rohan Journal: J Natl Cancer Inst Date: 1990-04-04 Impact factor: 13.506
Authors: H A Risch; J R McLaughlin; D E Cole; B Rosen; L Bradley; E Kwan; E Jack; D J Vesprini; G Kuperstein; J L Abrahamson; I Fan; B Wong; S A Narod Journal: Am J Hum Genet Date: 2001-02-15 Impact factor: 11.025
Authors: Marcia S Brose; Timothy R Rebbeck; Kathleen A Calzone; Jill E Stopfer; Katherine L Nathanson; Barbara L Weber Journal: J Natl Cancer Inst Date: 2002-09-18 Impact factor: 13.506
Authors: Tomas Kirchhoff; Jaya M Satagopan; Noah D Kauff; Helen Huang; Prema Kolachana; Crystal Palmer; Hannah Rapaport; Khedoudja Nafa; Nathan A Ellis; Kenneth Offit Journal: J Natl Cancer Inst Date: 2004-01-07 Impact factor: 13.506
Authors: Bethany L Niell; Gad Rennert; Joseph D Bonner; Ronit Almog; Lynn P Tomsho; Stephen B Gruber Journal: J Natl Cancer Inst Date: 2004-01-07 Impact factor: 13.506
Authors: Timothy L Cannon; Dominic W Lai; David Hirsch; Mark Delacure; Andrea Downey; Alexander R Kerr; Michael Bannan; Eleni Andreopoulou; Tamar Safra; Franco Muggia Journal: Oncologist Date: 2012-05-23
Authors: Anita Y Kinney; Laurie E Steffen; Barbara H Brumbach; Wendy Kohlmann; Ruofei Du; Ji-Hyun Lee; Amanda Gammon; Karin Butler; Saundra S Buys; Antoinette M Stroup; Rebecca A Campo; Kristina G Flores; Jeanne S Mandelblatt; Marc D Schwartz Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544
Authors: Matthew B Yurgelun; Matthew H Kulke; Charles S Fuchs; Brian A Allen; Hajime Uno; Jason L Hornick; Chinedu I Ukaegbu; Lauren K Brais; Philip G McNamara; Robert J Mayer; Deborah Schrag; Jeffrey A Meyerhardt; Kimmie Ng; John Kidd; Nanda Singh; Anne-Renee Hartman; Richard J Wenstrup; Sapna Syngal Journal: J Clin Oncol Date: 2017-01-30 Impact factor: 44.544
Authors: Janina Suchy; Cezary Cybulski; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Tadeusz Dębniak; Jacek Gronwald; Anna Jakubowska; Dominika Wokołorczyk; Grzegorz Kurzawski; Józef Kładny; Arkadiusz Jawień; Zbigniew Banaszkiewicz; Rafał Wiśniowski; Piotr Wandzel; Jacek Starzewski; Zbigniew Lorenc; Elżbieta Korobowicz; Piotr Krokowicz; Karolina Horbacka; Jan Lubiński; Steven A Narod Journal: Fam Cancer Date: 2010-12 Impact factor: 2.375
Authors: Brandie Heald; Heather Hampel; James Church; Beth Dudley; Michael J Hall; Maureen E Mork; Aparajita Singh; Elena Stoffel; Jessica Stoll; Y Nancy You; Matthew B Yurgelun; Sonia S Kupfer Journal: Fam Cancer Date: 2020-07 Impact factor: 2.375